As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Purple Biotech Ltd. The largest reported stake is Mitchell P. Kopin's, at 9.99%. 8 filings are on record since September 9, 2025 (Schedule 13G/A, May 13, 2026).
Sell to companies like Purple Biotech Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: G1 Execution Services, LLC · Sole voting: 25,694,000 · Shared voting: 26,532,000 · Sole dispositive: 25,694,000 · Shared dispositive: 26,532,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 282,513,535 · Sole dispositive: 0 · Shared dispositive: 282,513,535 · SCHEDULE 13G/A, 2026-05-13
- · Holder: Susquehanna Securities, LLC · Percent: 5.2% · SCHEDULE 13G
- · Holder: Mitchell P. Kopin · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: Mitchell P. Kopin · Percent: 9.99% · SCHEDULE 13G
Purple Biotech Ltd. has 8 Schedule 13D or 13G filings on record since 2025-09-09. 2 holders' latest filing reports 5% or more of ordinary shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.99% | 282,513,535 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 | |
| Lincoln Alternative Strategies LLC | 9.9% | 605,000 | SCHEDULE 13G, 2025-09-09 | 2025-09-04 |
| Orca Capital AG | 4.9% | 306,394 | SCHEDULE 13G/A, 2025-09-09 | 2025-09-04 |
| G1 Execution Services, LLC | 1.4% | 26,532,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Purple Biotech Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Purple Biotech Ltd. and the records around it.
Purple Biotech Ltd. elsewhere on the record
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
- G1 Execution Services, LLC also filed stake reports on 45 other companies: AmpliTech Group, Inc. (Aug 2026), Bitdeer Technologies Group (Aug 2026), Compass Diversified Holdings (Aug 2026)
Watch Purple Biotech Ltd.
Get an email when Purple Biotech Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Purple Biotech Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Purple Biotech Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Purple Biotech Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Mitchell P. Kopin | 0 | 282,513,535 | 0 | 282,513,535 | SCHEDULE 13G/A, 2026-05-13 |
| Daniel B. Asher | 0 | 282,513,535 | 0 | 282,513,535 | SCHEDULE 13G/A, 2026-05-13 |
| Intracoastal Capital LLC | 0 | 282,513,535 | 0 | 282,513,535 | SCHEDULE 13G/A, 2026-05-13 |
| G1 Execution Services, LLC | 25,694,000 | 26,532,000 | 25,694,000 | 26,532,000 | SCHEDULE 13G/A, 2026-08-14 |
| Susquehanna Securities, LLC | 838,000 | 26,532,000 | 838,000 | 26,532,000 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Purple Biotech Ltd. by CUSIP 74638P307 and gives its principal executive office as 4 Oppenheimer Street, Science Park, Rehovot (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-09 | Orca Capital AG | 9.9% | SCHEDULE 13G |
| 2025-09-09 | Orca Capital AG | 4.9% | SCHEDULE 13G/A |
| 2025-09-09 | Lincoln Alternative Strategies LLC | 9.9% | SCHEDULE 13G |
| 2025-09-10 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2025-11-07 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
| 2026-02-13 | Susquehanna Securities, LLC | 5.2% | SCHEDULE 13G |
| 2026-05-13 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | G1 Execution Services, LLC | 1.4% | SCHEDULE 13G/A |
Questions about who owns Purple Biotech Ltd.
Who owns Purple Biotech Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of Purple Biotech Ltd.: Mitchell P. Kopin (9.99%, Schedule 13G/A, filed 2026-05-13) and Lincoln Alternative Strategies LLC (9.9%, Schedule 13G, filed 2025-09-09).
Who are the largest shareholders of Purple Biotech Ltd.?
By the share each holder's latest filing reports, the largest holders of Purple Biotech Ltd. on this page are Mitchell P. Kopin (9.99%) and Lincoln Alternative Strategies LLC (9.9%).
When did Mitchell P. Kopin buy into Purple Biotech Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Mitchell P. Kopin on this page is the Schedule 13G, filed 2025-09-10, reporting 9.99%; its latest, Schedule 13G/A filed 2026-05-13, reports 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Purple Biotech Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.